Title: Cost-effectiveness of Public Health Screening for Pre-symptomatic Type 1 Diabetes with and without Treatment for Prevention of Type 1 Diabetes
Funding Body: Helmsley Trust
Funding Period: 2023-2025
Objectives:
To assess the long-term cost-effectiveness of the Fr1da screening and to explore the cost-effectiveness of novel treatment strategies (immune-therapies) in screen-detected kids
Background:
Studies like Fr1da and ASK showed that population-based screening for type 1 diabetes is feasible but also expensive. New immuno-therapies can delay the onset of type 1 diabetes, however, current costs for these medications are very high
Methods:
We will build and paramterize a health economic simulation model. For estimation of epidemiological and economic parameters we will analyze data of the DPV registry.
Impact:
The project adds important evidence for payers in Germany on the cost and health benefits of screening and screening plus novel treatment strategies
Contact: Katharina Schoder